Bayesian Capital Management, LP Exelixis, Inc. Transaction History

Bayesian Capital Management, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$14.96 - $17.39 $360,536 - $419,099	-24,100 Reduced 46.89%	27,300 $437,000
Q3 2022 Nov 14, 2022	BUY	$15.68 - $22.27 $805,952 - $1.14 Million	51,400 New	51,400 $806,000
Q2 2022 Aug 15, 2022	SELL	$17.44 - $23.16 $692,577 - $919,729	-39,712 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$17.03 - $22.67 $676,295 - $900,271	39,712 New	39,712 $900,000
Q3 2019 Nov 13, 2019	SELL	$17.68 - $22.65 $496,808 - $636,465	-28,100 Closed	0 $0
Q2 2019 Aug 13, 2019	SELL	$18.93 - $24.75 $872,673 - $1.14 Million	-46,100 Reduced 62.13%	28,100 $600,000
Q1 2019 May 14, 2019	SELL	$19.6 - $24.76 $58,800 - $74,280	-3,000 Reduced 3.89%	74,200 $1.77 Million
Q4 2018 Feb 13, 2019	BUY	$13.65 - $21.8 $490,035 - $782,620	35,900 Added 86.92%	77,200 $1.52 Million
Q3 2018 Nov 14, 2018	BUY	$15.87 - $22.4 $655,431 - $925,119	41,300 New	41,300 $732,000
Q1 2018 May 15, 2018	SELL	$22.15 - $31.89 $222,098 - $319,761	-10,027 Closed	0 $0
Q4 2017 Feb 12, 2018	BUY	$24.23 - $30.93 $242,954 - $310,135	10,027	10,027 $305,000

501

244M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.5B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Bayesian Capital Management, LP with notifications on news.